Results 21 to 30 of about 281,748 (215)

JAK2V617F allele burden in polycythemia vera: burden of proof

Blood, 2023
Visual ...
A. Moliterno, H. Kaizer, B. Reeves
semanticscholar   +1 more source

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Blood, 2022
Therapy for essential thrombocythemia (ET) and polycythemia vera (PV) is aimed at reducing thrombotic risk through normalizing blood counts. Mascarenhas et al report on a randomized trial of hydroxyurea (HU) vs pegylated interferon α (PEG) in 168 ...
J. Mascarenhas, H. Kosiorek, J. Prchal, A. Rambaldi, Dmitriy Berenzon, A. Yacoub, C. Harrison, M. McMullin, A. Vannucchi, J. Ewing, C. O'Connell, J. Kiladjian, A. Mead, E. Winton, D. Leibowitz, V. De Stefano, M. Arcasoy, C. Kessler, R. Catchatourian, D. Rondelli, R. Silver, A. Bacigalupo, A. Nagler, M. Kremyanskaya, M. Levine, J. A. Arango Ossa, E. McGovern, L. Sandy, M. Salama, V. Najfeld, J. Tripodi, N. Farnoud, A. Penson, R. Weinberg, L. Price, J. Goldberg, R. Marchioli, G. Tognoni, R. Rampal, R. Mesa, A. Dueck, R. Hoffman, T. Barbui   +42 more
semanticscholar   +1 more source

Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera

Blood Cancer Journal, 2022
We investigated the neutrophil-to-lymphocyte ratio (NLR) as a predictor of thrombosis in polycythemia vera (PV). After a median follow-up of 2.51 years, of 1508 PV patients enrolled in the ECLAP study, 82 and 84 developed arterial and venous thrombosis ...
A. Carobbio, A. Vannucchi, V. De Stefano, A. Masciulli, P. Guglielmelli, G. G. Loscocco, F. Ramundo, E. Rossi, Y. Kanthi, A. Tefferi, T. Barbui   +10 more
semanticscholar   +1 more source

Genetic Background of Polycythemia Vera

Genes, 2022
Polycythemia vera belongs to myeloproliferative neoplasms, essentially by affecting the erythroblastic lineage. JAK2 alterations have emerged as major driver mutations triggering PV-phenotype with the V617F mutation detected in nearly 98% of cases.
Mathilde Regimbeau, Romain Mary, F. Hermetet, F. Girodon   +3 more
semanticscholar   +1 more source

Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia

Journal of Hematology & Oncology, 2021
In a population of 42 Philadelphia negative myeloproliferative neoplasm patients, all on systemic active treatment, the likelihood of responding to anti-SARS-CoV-2 BNT162b2 vaccine at 2 weeks after the second dose was significantly lower in the ten ...
F. Pimpinelli, F. Marchesi, G. Piaggio, D. Giannarelli, E. Papa, P. Falcucci, A. Spadea, M. Pontone, S. di Martino, V. Laquintana, Antonia Marina La Malfa, E. D. Di Domenico, O. di Bella, Gianluca Falzone, F. Ensoli, B. Vujovic, A. Morrone, G. Ciliberto, A. Mengarelli   +18 more
semanticscholar   +1 more source

Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk‐stratification and management

American journal of hematology/oncology, 2020
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPN) respectively characterized by clonal erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding ...
A. Tefferi, T. Barbui
semanticscholar   +1 more source

Anesthetic management of a patient with polycythemia vera undergoing emergency repair of a type-A aortic dissection and concomitant coronary artery bypass grafting: a case report [PDF]

Korean Journal of Anesthesiology, 2015
Polycythemia vera is a chronic progressive myeloproliferative disease characterized by increased circulating red blood cells, and the hyperviscosity of the blood can lead to an increased risk of arterial thrombosis.
Hyeongwoo Im, Jeong Jin Min, Jaeyoung Yang, Sangmin Maria Lee, Jong Hwan Lee   +4 more
doaj   +1 more source

Aberrant expression of microRNA in polycythemia vera

Haematologica, 2008
Background Polycythemia vera is a clonal hematopoietic stem cell disorder in which the JAK2 V617F mutation is observed in >95% of patients, but an as yet unidentified process appears to initiate the clonal expansion of hematopoiesis.
Hana Bruchova, Michaela Merkerova, Josef T. Prchal   +2 more
doaj   +1 more source

Extent of hematopoietic involvement by TET2 mutations in JAK2V617F polycythemia vera

Haematologica, 2011
TET2 mutations are found in polycythemia vera and it was initially reported that there is a greater TET2 mutational burden than JAK2V617F in polycythemia vera stem cells and that TET2 mutations precede JAK2V617F.
Sabina I. Swierczek, Donghoon Yoon, Christine Bellanné-Chantelot, Soo Jin Kim, Cécile Saint-Martin, Francois Delhommeau, Albert Najman, Josef T. Prchal   +7 more
doaj   +1 more source

Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy

Haematologica, 2008
We analyzed the effect of hydroxyurea on the JAK2V617F allelic ratio (%JAK2V617F), measured in purified blood granulocytes, of patients with polycythemia vera and essential thrombocythemia.
François Girodon, Céline Schaeffer, Cédric Cleyrat, Morgane Mounier, Ingrid Lafont, Frédéric Dos Santos, Aurélie Vidal, Marc Maynadié, Sylvie Hermouet   +8 more
doaj   +1 more source